Comparison of [123I] metaiodobenzylguanidine kinetics with heart rate variability and plasma norepinephrine level

Journal of Nuclear Cardiology

Volumn 4, Issue 6, 1997, Pages 515-523

  Kurata, Chinori ^a   Shouda, Sakae ^b   Mikami, Tadashi ^b   Wakabayashi, Yasushi ^b   Nakano, Tomoyasu ^b   Sugiyama, Tsuyoshi ^b   Tawarahara, Kei ^b   Sakata, Kazuyuki ^b  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NONE

Author keywords

Heart rate variability; Norepinephrine; Sympathetic nervous system activity; 123I metaiodobenzylguanidine

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; NORADRENALIN; RADIOISOTOPE; (3 IODOBENZYL)GUANIDINE; RADIOPHARMACEUTICAL AGENT;

ADRENERGIC SYSTEM; ADULT; AGED; ARTICLE; AUTONOMIC NERVOUS SYSTEM FUNCTION; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG CLEARANCE; ELECTROCARDIOGRAPHY; FEMALE; HEART FUNCTION; HEART RATE VARIABILITY; HEART SCINTISCANNING; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; NORADRENALIN BLOOD LEVEL; PRIORITY JOURNAL; BLOOD; HEART; HEART RATE; INNERVATION; MIDDLE AGED; PHYSIOLOGY;

3-IODOBENZYLGUANIDINE; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HEART; HEART RATE; HUMANS; MALE; MIDDLE AGED; NOREPINEPHRINE; RADIOPHARMACEUTICALS; SYMPATHETIC NERVOUS SYSTEM;

EID: 0031283105     PISSN: 10713581     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1071-3581(97)90010-6     Document Type: Article

References (33)

1. Cohn JN, Levine TB, Olivari MT, Garburg V, Lura D, Francis GS, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819-23.
2. Masking GJ, Esler MD, Jennings GL, Burton D, Johns JA, Korner PI. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation 1986;73:615-21.
3. Kingwell BA, Thompson JM, Kaye DM, McPherson GA, Jennings GL, Esler MD. Heart rate spectral analysis, cardiac norepinephrine spillover, and muscle sympathetic nerve activity during human sympathetic nervous activation and failure. Circulation 1994;90: 234-40.
4. Akselrod S, Gordon D, Ubel FA, Shannon DC, Barger AC, Cohen RJ. Power spectrum analysis of heart rate fluctuations: a quantitative probe of beat-to-beat cardiovascular control. Science 1981; 213:220-2.
5. Malliani A, Pagani M, Lombardi F, Cerutti S. Cardiovascular neural regulation explored in the frequency domain. Circulation 1991;84:482-92.
6. Schofer J, Spielmann R, Schuchert A, Weber K, Schilder M. Iodine-123 meta-iodobenzylguanidine scintigraphy: a noninvasive method to demonstrate myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1988;12:1252-8.
7. Benedict CR, Shelton B, Johnstone DE, Francis G, Greenverg B, Konstam M, et al. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. Circulation 1996;94:690-7.
8. Bigger JT Jr, Fleiss JL, Steinman RC, Rolnitzky LM, Kleiger RE, Rottman JN. Frequency domain measures of heart period variability and mortality after myocardial infarction. Circulation 1992;85: 164-71.
9. Stein KM, Borer JS, Hochreiter C, Okin PM, Herrold EM, Devereux RB, et al. Prognostic value and physiological correlates of heart rate variability in chronic severe mitral regurgitation. Circulation 1993;88:127-135.
10. Merlet P, Valette H, Dobois-Rande J, Moyse D, Duboc D, Dove P, et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 1992;33:471-7.
11. Porter TR, Eckberg DL, Fritsch JM, Rea BF, Beightol LA, Schmedtje JF Jr, et al. Autonomic pathophysiology in heart failure: sympathetic-cholinergic interrelations. J Clin Invest 1990;85:1362-71.
12. Kienzle MG, Ferguson DW, Birkett CL, Myers GA, Berg WJ, Mariano DJ. Clinical, hemodynamic and sympathetic neural correlates of heart rate variability in congestive heart failure. Am J Cardiol 1992;69:761-7.
13. 131I]iodobenzylguanidine (I-131 MIBG) and circulating catecholamines in suspected pheochromocytoma. J Nucl Med 1983; 24:1127-34.
14. 123I]metaiodobenzylguanidine scintigraphy. Circulation 1994;89:2843-51.
15. Langer A, Freeman MR, Josse RG, Armstrong PW. Metaiodobenzylguanidine imaging in diabetes mellitus: assessment of cardiac sympathetic denervation and its relation to autonomic dysfunction and silent myocardial ischemia. J Am Coll Cardiol 1995;25:610-8.
16. 43K and the scintillation camera. Circ Res 1973;33:113-22.
17. 123I-metaiodobenzylguanidine from the heart in patients with chronic renal failure on dialysis. J Nucl Med 1995;36:2037-43.
18. Malliani A, Lombardi F, Pagani M. Power spectrum analysis of heart rate variability: a tool to explore neural regulatory mechanisms. Br Heart J 1994;71:1-2.
19. Montano N, Ruscone TG, Porta A, Lombardi F, Pagani M, Malliani A. Power spectrum analysis of heart rate variability to assess the changes in sympathovagal balance during graded orthostatic tilt. Circulation 1994;90:1826-31.
20. Malik M, Camm AJ. Components of heart rate variability - what they really mean and what we really measure. Am J Cardiol 1993;72:821-2.
21. 123I-mIBG in rats. Nucl Med Commun 1988;9:663-7.
22. Henderson EB, Kahn JK, Corbett JR, Jansen DE, Pippin JJ, Kulkarni P, et al. Abnormal I-123 metaiodobenzylguanidine myocardial washout and distribution may reflect myocardial adrenergic derangement in patients with congestive cardiomyopathy, Circulation 1988;78:1192-9.
23. Nakajo M, Shimabukuro K, Yoshimura H, Yonekura R, Nakabeppu Y, Tanoue, et al. Iodine-131 metaiodobenzylguanidine intra- and extravesicular accumulation in the rat heart. J Nucl Med 1986;27:84-9.
24. Nakajo M, Shimabukuro K, Miyaji N, Shimada J, Shirono K, Sakata H, et al. Rapid clearance of iodine-131 MIBG from the heart and liver of patients with adrenergic dysfunction and pheochromocytoma. J Nucl Med 1985;26:357-65.
25. Rabinovitch MA, Rose CP, Schwab AJ, Fitchett DH, Honos GN, Stewart JA, et al. A method of dynamic analysis of iodine-123-metaiodobenzylguanidine scintigrams in cardiac mechanical overload hypertrophy and failure. J Nucl Med 1993;34:589-600.
26. Glowniak JV, Turner FE, Gray LL, Palac RT, Lagunas-Solar MC, Woodward WR. Iodine-123 metaiodobenzylguanidine imaging of the heart in idiopathic congestive cardiomyopathy and cardiac transplants. J Nucl Med 1989;30:1182-91.
27. Spinnler MT, Lombardi F, Moretti C, Sandrone G, Podio V, Spandonari T, et al. Evidence of functional alterations in sympathetic activity after myocardial infarction. Eur Heart J 1993;14: 1334-43.
28. Esler MD, Thompson JM, Kaye DM, Turner AG, Jennings GL, Cox HS, et al. Effects of aging on the responsiveness of the human cardiac sympathetic nerves to Stressors. Circulation 1995;91: 351-8.
29. Sheldon RS, Wilson WL. Clinical assessment of measures of heart period variability from ambulatory monitors using Fourier analysis [abstract]. Circulation 1994;90(suppl 1):I-330.
30. Goldsmith RL, Bigger JT, Steinman RC, Fleis JL. Comparison of 24-hour parasympathetic activity in endurance-trained and untrained young men. J Am Coll Cardiol 1992;20:552-8.
31. Huikuri HV, Kessler KM, Terracall E, Castellanos A, Linnaluoto MK, Myerburg RJ. Reproducibility and circadian rhythm of heart rate variability in healthy subjects. Am J Cardiol 1990; 65:391-3.
32. Van Hoogenhuyze D, Weinstein N, Martin GJ, Weiss JS, Schaad JD, Sahyouni XN, et al. Reproducibility and relation to mean heart rate of heart rate variability in normal subjects and in patients with congestive heart failure secondary to coronary heart disease. Am J Cardiol 1991;68 1668-76.
33. Stein PK, Rich MW, Rottman JN, Kleiger RE. Stability of index heart rate variability in patients with congestive heart failure. Am Heart J 1995;129:975-81.